Development of a method for early and minimally invasive diagnosis, severity assessment, and treatment response evaluation of cardiac amyloidosis using a hybrid amyloid imaging method combining 18F-Flutemetamol-PET and 99mTc-HMDP scintigraphy

Development of a method for early and minimally invasive diagnosis, severity assessment, and treatment response evaluation of cardiac amyloidosis using a hybrid amyloid imaging method combining 18F-Flutemetamol-PET and 99mTc-HMDP scintigraphy - Cardiac amyloidosis research using Vizamyl and Clearborn

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000057246

Enrollment

100

Registered

2025-03-10

Start date

2025-02-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyloidosis

Interventions

18F-Flutemetamol-PET and 99mTc-HMDP scintigraphy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 years or older who have been definitively diagnosed with amyloidosis 2.Patients who are able to express their will and have voluntarily agreed to participate in the study, or patients who are unable to express their will and have their proxy consent to participate in the study

Exclusion criteria

Exclusion criteria: 1.Patients with a history of allergies to the study drug 2.Other subjects who the principal investigator deems inappropriate to be subjects

Design outcomes

Primary

Measure	Time frame
The intensity and pattern of cardiac accumulation of two types of tracers (99mTc-HMDP and 18F-Flutemetamol), the relationship between the intensity and clinical parameters, and the time course of the accumulation if positive.	—

Secondary

Measure	Time frame
Detectability of amyloid deposits in organs other than the heart using two imaging methods	—

Countries

Japan

Contacts

Public ContactNagaaki Katoh

Shinshu University School of Medicine Department of Medicine (Neurology and Rheumatology)

nagaaki@shinshu-u.ac.jp0263-37-2673

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026